PDF(Pubmed)
Abstract：
BACKGROUND: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder with significant metabolic implications, including an increased risk of cardiovascular diseases and diabetes. Kallistatin, a serine proteinase inhibitor with anti-inflammatory and antioxidative properties, has been identified as a potential biomarker for PCOS due to its role in modulating inflammation and oxidative stress.
METHODS: This prospective cohort study was conducted at a university hospital\'s gynecology clinic. It included 220 women diagnosed with PCOS and 220 healthy controls matched for age and body mass index. Kallistatin levels were quantitatively assessed using enzyme-linked immunosorbent assay (ELISA) techniques. Associations between kallistatin levels and clinical manifestations of PCOS, including hyperandrogenism and metabolic profiles, were examined.
RESULTS: Kallistatin levels were significantly lower in patients with PCOS (2.65 ± 1.84 ng/mL) compared to controls (6.12 ± 4.17 ng/mL; p < 0.001). A strong negative correlation existed between kallistatin levels and androgen concentrations (r = -0.782, p = 0.035). No significant associations were found between kallistatin levels and insulin resistance or lipid profiles.
CONCLUSIONS: The findings indicate that reduced kallistatin levels are closely associated with PCOS and could serve as a promising biomarker for its diagnosis. The specific correlation with hyperandrogenism suggests that kallistatin could be particularly effective for identifying PCOS subtypes characterized by elevated androgen levels. This study supports the potential of kallistatin in improving diagnostic protocols for PCOS, facilitating earlier and more accurate detection, which is crucial for effective management and treatment.
METHODS: This prospective cohort study was conducted at a university hospital\'s gynecology clinic. It included 220 women diagnosed with PCOS and 220 healthy controls matched for age and body mass index. Kallistatin levels were quantitatively assessed using enzyme-linked immunosorbent assay (ELISA) techniques. Associations between kallistatin levels and clinical manifestations of PCOS, including hyperandrogenism and metabolic profiles, were examined.
RESULTS: Kallistatin levels were significantly lower in patients with PCOS (2.65 ± 1.84 ng/mL) compared to controls (6.12 ± 4.17 ng/mL; p < 0.001). A strong negative correlation existed between kallistatin levels and androgen concentrations (r = -0.782, p = 0.035). No significant associations were found between kallistatin levels and insulin resistance or lipid profiles.
CONCLUSIONS: The findings indicate that reduced kallistatin levels are closely associated with PCOS and could serve as a promising biomarker for its diagnosis. The specific correlation with hyperandrogenism suggests that kallistatin could be particularly effective for identifying PCOS subtypes characterized by elevated androgen levels. This study supports the potential of kallistatin in improving diagnostic protocols for PCOS, facilitating earlier and more accurate detection, which is crucial for effective management and treatment.
摘要：
背景：多囊卵巢综合征（PCOS）是一种普遍存在的内分泌疾病，具有重要的代谢意义，包括心血管疾病和糖尿病的风险增加。Kallistatin,一种具有抗炎和抗氧化特性的丝氨酸蛋白酶抑制剂，由于其在调节炎症和氧化应激中的作用，已被确定为PCOS的潜在生物标志物。
方法：这项前瞻性队列研究在一所大学医院的妇科诊所进行。它包括220名诊断为PCOS的女性和220名年龄和体重指数相匹配的健康对照。使用酶联免疫吸附测定（ELISA）技术定量评估Kallistatin水平。Kallistatin水平与PCOS临床表现之间的关系，包括高雄激素血症和代谢谱，进行了检查。
结果：PCOS患者的Kallistatin水平（2.65±1.84ng/mL）明显低于对照组（6.12±4.17ng/mL；p<0.001）。钾盐抑制素水平与雄激素浓度之间存在强烈的负相关（r=-0.782，p=0.035）。在kallistatin水平与胰岛素抵抗或血脂谱之间没有发现显着关联。
结论：研究结果表明，降低的激肽素水平与PCOS密切相关，可以作为诊断PCOS的有希望的生物标志物。与高雄激素血症的特定相关性表明，kallistatin对于鉴定以雄激素水平升高为特征的PCOS亚型可能特别有效。这项研究支持了kallistatin在改善PCOS诊断方案方面的潜力，促进更早和更准确的检测，这对于有效的管理和治疗至关重要。
方法：这项前瞻性队列研究在一所大学医院的妇科诊所进行。它包括220名诊断为PCOS的女性和220名年龄和体重指数相匹配的健康对照。使用酶联免疫吸附测定（ELISA）技术定量评估Kallistatin水平。Kallistatin水平与PCOS临床表现之间的关系，包括高雄激素血症和代谢谱，进行了检查。
结果：PCOS患者的Kallistatin水平（2.65±1.84ng/mL）明显低于对照组（6.12±4.17ng/mL；p<0.001）。钾盐抑制素水平与雄激素浓度之间存在强烈的负相关（r=-0.782，p=0.035）。在kallistatin水平与胰岛素抵抗或血脂谱之间没有发现显着关联。
结论：研究结果表明，降低的激肽素水平与PCOS密切相关，可以作为诊断PCOS的有希望的生物标志物。与高雄激素血症的特定相关性表明，kallistatin对于鉴定以雄激素水平升高为特征的PCOS亚型可能特别有效。这项研究支持了kallistatin在改善PCOS诊断方案方面的潜力，促进更早和更准确的检测，这对于有效的管理和治疗至关重要。
